Published in Neuro Oncol on July 28, 2013
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ (2014) 1.32
Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. Genes Dis (2015) 1.05
The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells. J Cereb Blood Flow Metab (2014) 0.86
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle (2015) 0.83
Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation. Oncotarget (2016) 0.80
Placental ABC Transporters: Biological Impact and Pharmaceutical Significance. Pharm Res (2016) 0.79
Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Rev Mol Diagn (2015) 0.77
High-Throughput Analysis of Global DNA Methylation Using Methyl-Sensitive Digestion. PLoS One (2016) 0.75
Selective GPR55 antagonism reduces chemoresistance in cancer cells. Pharmacol Res (2016) 0.75
Thermodynamics in Gliomas: Interactions between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma. Front Physiol (2017) 0.75
Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell (2009) 18.31
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res (2004) 14.73
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer (2006) 8.50
Brain tumour stem cells. Nat Rev Cancer (2006) 5.84
A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J Neurosci (1992) 4.60
WNT signaling pathway and stem cell signaling network. Clin Cancer Res (2007) 4.24
MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) (2007) 4.04
FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell (2011) 3.58
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology (2011) 3.14
Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ (2006) 3.12
Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev (2006) 2.95
Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs (2009) 2.90
Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene (2007) 2.82
Glioma stem cells: a midterm exam. Neuron (2008) 2.69
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell (2010) 2.68
Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia (2006) 1.82
Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. Mol Cancer (2011) 1.64
Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene (2002) 1.59
New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol (2008) 1.58
Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells (2007) 1.53
CD133 identifies perivascular niches in grade II-IV astrocytomas. J Neurooncol (2008) 1.42
The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene (2009) 1.37
Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol (1996) 1.29
Molecular targeting of glioblastoma: Drug discovery and therapies. Trends Mol Med (2011) 1.27
Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res (2005) 1.26
The ABCG2 resistance network of glioblastoma. Cell Cycle (2009) 1.24
Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res (2010) 1.23
Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer (2004) 1.19
Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. Mol Cancer Ther (2007) 1.13
Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype. Neuropathol Appl Neurobiol (2009) 1.10
Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest (2009) 1.06
A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol (2008) 1.04
Developmental signaling pathways in brain tumor-derived stem-like cells. Dev Dyn (2007) 1.02
Increase in proliferation and differentiation of neural progenitor cells isolated from postnatal and adult mice brain by Wnt-3a and Wnt-5a. Mol Cell Biochem (2006) 1.01
Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. Int J Radiat Oncol Biol Phys (2009) 0.96
Primary brain tumors, neural stem cell, and brain tumor cancer cells: where is the link? Neuropharmacology (2010) 0.93
Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide. Anticancer Drugs (1999) 0.92
Glioma stem cells: their role in chemoresistance. World Neurosurg (2012) 0.91
The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells. Neuro Oncol (2012) 0.90
Gliotypic neural stem cells transiently adopt tumorigenic properties during normal differentiation. Stem Cells (2009) 0.90
Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy. Cell Mol Neurobiol (2009) 0.90
Antigenic and Genotypic Similarity between Primary Glioblastomas and Their Derived Neurospheres. J Oncol (2011) 0.88
CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas. Int J Cancer (2009) 0.87
Digoxin and ouabain increase the synthesis of cholesterol in human liver cells. Cell Mol Life Sci (2009) 0.83
Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res (2006) 1.89
A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells. J Control Release (2010) 1.63
REST controls self-renewal and tumorigenic competence of human glioblastoma cells. PLoS One (2012) 1.58
The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic Biol Med (2012) 1.53
Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med (2010) 1.52
Classical inhibitors of NOX NAD(P)H oxidases are not specific. Curr Drug Metab (2008) 1.39
Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress. J Biol Chem (2004) 1.39
SOX2 expression and amplification in gliomas and glioma cell lines. Cancer Genomics Proteomics (2011) 1.35
IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol (2011) 1.31
Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res (2005) 1.26
HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer (2012) 1.15
Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells. J Immunol (2011) 1.13
Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma. Int J Cancer (2006) 1.08
Does vitreous silica contradict the toxicity of the crystalline silica paradigm? Chem Res Toxicol (2010) 1.07
Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation. FEBS Lett (2003) 1.03
mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma. Anticancer Res (2009) 1.00
Cytotoxicity of zinc-containing bioactive glasses in contact with human osteoblasts. Chem Biol Interact (2007) 0.99
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. PLoS One (2013) 0.98
Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. Mol Cancer (2013) 0.96
MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors. J Neurooncol (2012) 0.95
On the origin and growth of gliomas. Anticancer Res (2010) 0.95
Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes. Diabetes (2010) 0.95
Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm (2011) 0.94
The NADPH oxidase inhibitor apocynin (acetovanillone) induces oxidative stress. Toxicol Appl Pharmacol (2005) 0.93
The NADPH oxidase inhibitor apocynin induces nitric oxide synthesis via oxidative stress. Toxicol Appl Pharmacol (2007) 0.93
Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol (2008) 0.93
RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells. Mol Cancer Res (2008) 0.92
High aspect ratio materials: role of surface chemistry vs. length in the historical "long and short amosite asbestos fibers". Inhal Toxicol (2010) 0.92
Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. Biochem J (2011) 0.91
Nanoparticle- and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrier. Curr Drug Metab (2013) 0.91
Molecular genetic changes in a series of neuroepithelial tumors of childhood. J Neurooncol (2002) 0.90
iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. Mol Cancer (2009) 0.89
Na+/H+ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. Int J Cancer (2005) 0.89
Cycling of NADPH by glucose 6-phosphate dehydrogenase optimizes the spectrophotometric assay of nitric oxide synthase activity in cell lysates. Nitric Oxide (2006) 0.89
Nestin expression in reactive astrocytes of human pathology. J Neurooncol (2006) 0.89
Potential toxicity of nonregulated asbestiform minerals: balangeroite from the western Alps. Part 3: Depletion of antioxidant defenses. J Toxicol Environ Health A (2005) 0.89
Absence of soluble CD14 in saliva of young patients with dental caries. Eur J Oral Sci (2007) 0.88
Antigenic and Genotypic Similarity between Primary Glioblastomas and Their Derived Neurospheres. J Oncol (2011) 0.88
MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics Proteomics (2009) 0.88
Nitric oxide stimulates human sperm motility via activation of the cyclic GMP/protein kinase G signaling pathway. Reproduction (2010) 0.87
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. Blood (2012) 0.87
Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. J Cell Mol Med (2011) 0.87
Survivin expression in glioblastomas correlates with proliferation, but not with apoptosis. Anticancer Res (2008) 0.86
Expression of cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors in oligodendrogliomas in humans. Neurosci Lett (2003) 0.85
Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets. J Neurooncol (2003) 0.85
MGMT hypermethylation and MDR system in glioblastoma cancer stem cells. Cancer Genomics Proteomics (2012) 0.85
Hematite nanoparticles larger than 90 nm show no sign of toxicity in terms of lactate dehydrogenase release, nitric oxide generation, apoptosis, and comet assay in murine alveolar macrophages and human lung epithelial cells. Chem Res Toxicol (2012) 0.84
Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1alpha in human colon cancer cells. Toxicol Appl Pharmacol (2009) 0.84
Association among oral health, apical periodontitis, CD14 polymorphisms, and coronary heart disease in middle-aged adults. J Endod (2012) 0.83